An Evolving Perspective on Smoking Cessation Therapies

Transcription

1 An Evolving Perspective on Smoking Cessation Therapies Andrew Pipe, CM, MD Chief, Division of Prevention & Rehabilitation University of Ottawa Heart Institute

2 Faculty/Presenter Disclosure Andrew Pipe, CM, MD Grants/ Research Support: Consulting Fees: Speakers Bureau/Honoraria Pfizer AMGEN Pfizer Pfizer

3 Mitigating Potential Bias I will describe evidence-based, best-practice approaches to smoking cessation. I will discuss the off-label use of medications.

4 Smoking Rates - Canada Daily Current Male: 16% 21% Female: 11% 14% Ottawa Male: 10% 16% Female: 8% 13%

5 Smoking Cessation The Most Important Preventive Intervention!

6

7 Stalking The Zombies of Smoking Cessation Misconceptions that won t die off!

8 Zombies are everywhere!

9

10 Cost Effectiveness per life-year saved: Smoking Cessation $ 2,000 6,000 R x of Hypertension $ 9,000 26,000 R x of Hyperlipidemia $ 50, ,000 Benowitz NL Prog Cardiovasc Dis 2003;46:91-111

11 Smoking is a Habit

12 Probability of dependence after trying a substance at least once Tobacco 32% Heroin 23% Cocaine 17% Alcohol 15% Stimulants 11% Anxiolytics 9% Cannabis 9% Analgesics 8% Inhalants 4% Stahl s Essential Psychopharmacology, 3 rd ed. 2008

13 A Cigarette is just a Cigarette

14 A Drug Delivery Device

15

16 Cessation is Easy! ( It s all about willpower! )

17 FOREBRAIN Dopamine BRAIN STEM α 4 ß 2 receptors

18 Guide your Patients to a Smoke Free Future. CCSH. 1991

19 A smoker is a smoker is a smoker

20 The Hardened Smoker 30% of current smokers are said to have psychiatric co-morbidities! 44% of all cigarettes are consumed by individuals with psychiatric co-morbidities!

21 Persons with chronic mental illness die 25 years earlier than others Tobacco addiction is the major contributor to that premature mortality. Annu Rev Public Health 2010;31:

22 Depression and Smoking Farrell et al. Int Rev Psychiatry. 2003;15:43-49; Mackay et al. The Tobacco Atlas. 2nd ed

23 Monoamine Oxidase Monoamine Oxidase Inhibition

24 Smoking & Symptomatology In patients with schizophrenia, smoking may be associated with improvements in specific symptoms and cognitive measures Compton et al. Harv Rev Psychiatry. 2006;14(4): ;.

25 Caffeine Ingestion Caffeine metabolism altered by cessation Caffeine levels may rise: 2-3 x higher! Consider reducing caffeine intake Consider substituting de-caffeinated drinks Be aware of similarities between caffeinism and withdrawal symptoms

26 Cessation is Easy! ( It s all about willpower! )

27 Herbal Preparations and Cessation

28 Conclusions: In this randomized trial, SJW did not increase smoking cessation rates. Our data suggest that SJW has little role in the treatment of tobacco dependence.

29 Authors Conclusions: There is no evidence available form long-term trials that lobeline can aid smoking cessation, and the short-term evidence suggests there is no benefit.

30 Pharmacotherapy 3 First Line Therapies NRT All smokers trying to quit, except in the bupropion presence of special circumstances, varenicline should receive pharmacotherapy for smoking cessation.

31 Second-Line Therapies Clonidine an effective smoking cessation treatment may be used under a physician s supervision as a second-line agent Nortryptiline an effective smoking cessation treatment may be used under a physician s supervision as a second-line agent Treating Tobacco Use and Dependence: 2008 Update

32 Nicotine Replacement Therapy Rationale Products The Patch Chewing Pieces Lozenges Nicotine Inhaler Nicotine Spray Advantages Shortcomings

33 Therapeutic Gap Guide your Patients to a Smoke Free Future. CCSH. 1991

34 A Smoke-free Future Sometimes the doorway has to be opened wider, or held open longer

35 Titrate Therapy: Dose Duration Combination

36 Standard Orders 1 pack a day 21 mg + and Inhaler 2 packs a day 42 mg + and Inhaler 3 packs a day further titration prn In every case recognize the need for titration

37 You can t use NRT in cardiac patients!

38 Zombie Concepts The safety of nicotine-replacement therapy in cardiovascular disease patients is supported by data from randomized trials, efficacy studies, observational data and physiologic studies. Joseph AM, Fu, Progress in Cardiovascular Diseases 2003;45:

39 NRT and CV Risk Clinical trials of NRT in patients with underlying, stable cardiovascular disease suggest that nicotine does not increase cardiovascular risk. Benowitz NL, Gourlay SG. J Am Coll Cardiol 1997;29:

40 NRT and CV Risk The use of nicotine patches did not cause aggravation of myocardial ischemia or rrhythmia in coronary patients and therefore an be used as a method to promote smoking cessation in this high-risk group. Tzivoni D, Keren A, Meyler et al. Cardiovasc Drugs Ther 1998;12:

41 NRT and CV Risk High-dose nicotine treatment, even with concomitant smoking, caused no short-term adverse effects on the cardiovascular system. Zevin S, Peyton J, Benowitz NL. Clin Pharmacol Ther 1998;64:87-95.

42 NRT and CV Risk The use of NRT is not associated with any increase in the risk of myocardial infarction, stroke, or death. N = 33,247 Hubbard R, Lewis S, et al. Tobacco Control 2005;14:

43 NRT and CV Risk Patients with pre-existing cardiovascular disease represent one of the groups most likely to benefit from smoking cessation and our results should encourage the use of NRT in these individuals. Hubbard R, Lewis S, et al. Tobacco Control 2005;14:

44 UOHI Smoking Cessation Programme Use of NRT in the Cardiac Setting Smoking Patients NRT Male NRT Female NRT ACS % ACS NRT ,016 (23%) 194 (19%) 149 (20%) 45 (17%) (39%) , (44%) 477 (46%) 180 (41%) (63%) , (60%) 453 (60%) 185 (60%) (70%)

45 We found evidence that all forms of NRT made it more likely that a person s attempt to quit smoking would succeed. The chances of stopping smoking were increased by 50% to 70%. NRT works with or without additional counselling, and does not need to be prescribed by a doctor. Heavier smokers may need higher doses of NRT. There is no evidence that NRT increases the risk of heart attacks.

46 Harm reduction potential Vapour vs. Smoke Cessation of smoking? Dual-Use? Tobacco industry Perpetuation of smoking? Initiation of smoking? Adolescents? The E-cigarette.

47

48

49

50 Varenicline H N Varenicline N N α4ß2 receptor Influences neurotransmitters and receptors Addresses the neurochemistry of addiction

51 N Varenicline α4ß2 receptor

52 Varenicline -- Side Effects Nausea Headache Sleep disturbances Neuropsychiatric issues? Cardiovascular Issues?

53 Varenicline Causes Psychiatric Problems

54 Systematic studies do not support the view that varenicline causes neuropsychiatric side effects other than sleep disturbance and vivid dreams. Expert Opin Pharmacother 2011;12(11):

55 Our findings were consistent with an observational study* of 63,265 NRT users and 10,973 varenicline users that showed no increased risk of self-harm, depression, or suicidal ideation for varenicline compared to NRT Addiction 2012; doi: /j x Epub ahead of print *BMJ 2009;339:b3805

56 Varenicline causes CV problems* * This zombie was first sighted in Canada

57 Placebo Varenicline Risk of CV Events: 0.82% 1.06%

58 Efficacy and Safety of Varenicline for Smoking Cessation in Patients with Cardiovascular Disease: A Randomized Controlled Trial Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S. Circulation 2010;121(2):221-9

59

60 Meta-analysis of all published, randomised controlled trials found no significant increase in cardiovascular serious adverse events associated with varenicline use. BMJ 2012;344:e2856

61

62 Cardiovascular Events Associated With Smoking Cessation Pharmacotherapies: A Network Meta-Analysis Mills EJ et al. Circulation 2014;129:28-41 Smoking cessation therapies do not appear to raise the risk of serious cardiovascular disease events.

63 Medication Effectiveness Medication Number of arms Estimated odds ratio % Estimated abstinence rate Placebo Varenicline (2 mg/d) ( ) 33.2 ( ) Nicotine patch ( ) 23.4 ( ) Nicotine gum ( ) 19.0 ( ) Bupropion SR ( ) 24.2 ( ) Patch + Gum (ad lib) ( ) 36.5 ( ) Patch + Bupropion ( ) 28.9 ( ) Treating Tobacco Use and Dependence. Clinical Practice Guideline. US DHHS

64 Cessation is the responsibility of the Family Physician.

65 Assistance with smoking cessation is a fundamental responsibility of any practitioner who sees patients who are smokers.

66 Physician s Advice Clear Strong Personalized unambiguous and non-judgmental Matched by an institutional commitment to best practice!

67 The Ottawa Model Identification Documentation Counseling Pharmacotherapy Long-term follow-up Reid RD, Pipe AL, Quinlan B. Can J Cardiol 2006;22:

68 Smoking Cessation The single, most powerful, preventive intervention in clinical practice. Woolf SH. JAMA 1999;282(24):

69 Transforming Patient Care Professional Behaviours Institutional Practices

70

71

72